Current Atherosclerosis Reports

, Volume 11, Issue 1, pp 36–42 | Cite as

Should we treat all primary prevention patients with statins?

Article
  • 33 Downloads

Abstract

3-Hydroxy-3-methylglutary coenzyme A (HMG-CoA) reductase inhibitors have been shown to reduce cardiac events in different high-risk and medium-risk patient groups. Although there are other medications to lower cholesterol, evidence that these agents will provide protection from initial cardiac events is limited or does not exist. Also, although many physicians advocate combining second agents with statins to improve certain lipid fractions, evidence of improved reduction of initial cardiac events from these combinations is also lacking. Therefore, aggressive use of HMG-CoA reductase inhibitors remains the proven treatment to treat lipid abnormalities in primary patients.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Shepherd J, Cobbe JM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men high hypercholesterolemia. N Engl J Med 1995, 333:1301–1307.PubMedCrossRefGoogle Scholar
  2. 2.
    Ford I, Murray H, Packard CJ, et al.: Long-term follow-up of the West of Scotland coronary Prevention Group. N Engl J Med 2007, 357:1477–1485.PubMedCrossRefGoogle Scholar
  3. 3.
    Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels (AFCAPS/TexCAPS). JAMA 1998, 279:1615–1622.PubMedCrossRefGoogle Scholar
  4. 4.
    Gotto AM, Whitney E, Stein EA, et al.: Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas coronary Atherosclerosis prevention study. Circulation 2000, 101:477–495.PubMedGoogle Scholar
  5. 5.
    Sever PS, Dahlof NR, Wedel H, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients how have average or lower-that-average cholesterol concentrations (ASCOT-LLA). Lancet 2003, 361:1149–1158.PubMedCrossRefGoogle Scholar
  6. 6.
    Shepherd J, Blauw GJ, Murphy MB, et al.: Pravastatin in elderly patients as risk of vascular disease (PROSPER). Lancet 2002, 360:1623–1630.PubMedCrossRefGoogle Scholar
  7. 7.
    Shepherd J, Blauw GJ, Murphy MB, et al.: The design of a prospective study of pravastatin in the elderly at risk (PROSPER). Am J Cardiol 1999, 84:1192–1197.PubMedCrossRefGoogle Scholar
  8. 8.
    Mizuno K, Nakaya N, Ohashi Y, et al.: Usefulness of pravastatin in primary prevention of cardiovascular events in women (MEGA). Circulation 2008, 117:494–502.PubMedCrossRefGoogle Scholar
  9. 9.
    ALLHAT Collaborative Research Group: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care. JAMA 2002, 288:2998–3007.CrossRefGoogle Scholar
  10. 10.
    Pasternak RC: The ALLHAT Lipid Lowering Trial—less is less. JAMA 2002, 288:3042–3044.PubMedCrossRefGoogle Scholar
  11. 11.
    Ridker PM, for the JUPITER Study Group: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity c-reactive protein: rationale and design of the JUPITER Trial. Circulation 2003, 108:2292–2297.CrossRefGoogle Scholar
  12. 12.
    Crestor Outcomes Study JUPITER Closes Early Due To Unequivocal Evidence of Benefit [press release]. London, UK: AstraZeneca; March 31, 2008.Google Scholar
  13. 13.
    Lipid Research clinics program: The Lipid Research clinics coronary primary prevention trial results (LRC-CPPT). JAMA 1984, 251:351–364.CrossRefGoogle Scholar
  14. 14.
    Gotto AM: Contemporary Diagnosis and Management of Lipid Disorders, edn 3. Newtown, PA: Handbooks in Health Care; 2004:216.Google Scholar
  15. 15.
    Committee of Principal Investigators: A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978, 40:1069–1118.CrossRefGoogle Scholar
  16. 16.
    Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360–381.CrossRefGoogle Scholar
  17. 17.
    Frick MH, Elo O, Happa K, et al.: Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987, 317:1237–1245.PubMedGoogle Scholar
  18. 18.
    Manninen V, Elo MO, Frick MH, et al.: Lipid alterations and decline in the incidenxce of coronary heart disease in the Helsinki Heart Study [abstract]. JAMA 1988, 260:641.PubMedCrossRefGoogle Scholar
  19. 19.
    Tenkanen L, Manttari M, Kovanen PT, et al.: Gemfibrozil in the treatment of dyslipidemia. Arch Intern Med 2006, 166:743–748.PubMedCrossRefGoogle Scholar
  20. 20.
    Rubins HB, Ropins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary hears disease in men with low levels of high-density lipoprotein cholesterol (VA-HIT). N Engl J Med 1999, 341:410–418.PubMedCrossRefGoogle Scholar
  21. 21.
    Robins SJ, Collins D, Wittes JT, et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events (VA-HIT). JAMA 2001, 285:1585–1591.PubMedCrossRefGoogle Scholar
  22. 22.
    FIELD Study Investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study). Lancet 2005, 366:1849–1861.CrossRefGoogle Scholar
  23. 23.
    BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary heart disease. Circulation 2000, 102:21–36.Google Scholar
  24. 24.
    Canner PL, Berge KG, Wenger NK, et al.: Fifteen year mortality in Coronary Drug project patients: Long-Term benefits with niacin. J Am Coll Cardiol 1986, 8:1245–1255.PubMedCrossRefGoogle Scholar
  25. 25.
    Arntz HR, Agrawal R, Wunderlich W, et al.: Beneficial effects of pravastatin (+/- colestyramine/niacin) initiated immediately after a coronary event (L-CAD Study). Am J Cardiol 2000, 86:1293–1298.PubMedCrossRefGoogle Scholar
  26. 26.
    Stewart BF, Brown BG, Zhao XQ, et al.: Benefits of lipidlowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. J Am Coll Cardiol 1994, 23:899–906.PubMedGoogle Scholar
  27. 27.
    Blankenhorn DH, Nessim SA, Johnson RL, et al.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987, 257:3233–3240.PubMedCrossRefGoogle Scholar
  28. 28.
    Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223:405–418.PubMedGoogle Scholar
  29. 29.
    Elam MB, Hunnihake DB, Davis KB, et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease (ADMIT). JAMA 2000, 284:1263–1270.PubMedCrossRefGoogle Scholar
  30. 30.
    Zetia [package insert]. North Wales, PA: Merck-Schering-Plough Pharmaceuticals; 2007.Google Scholar
  31. 31.
    Merck/Schering-Plough Pharmaceuticals Provides Results of the ENHANCE Trial [press release]. North Wales, PA: Merck/Schering-Plough Pharmaceuticals; January 14, 2008.Google Scholar
  32. 32.
    Barter PJ, Caulfield M, Eriksson M, et al.: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109–2122.PubMedCrossRefGoogle Scholar
  33. 33.
    Guthrie RM: How safe is aggressive statin therapy? Prog Cardiovasc Nurs 2006, Summer:140–145.CrossRefGoogle Scholar
  34. 34.
    Davidson MH, Carlson DM, Guthrie RM, et al.: ABT-335 in combination with rosuvastatin improves multiple lipid ratios in patients with mixed dyslipidemia. J Clin Lipidol 2008, 2:211–212.CrossRefGoogle Scholar
  35. 35.
    Gisnberg HN, Bonds DE, Lovato LC, et al.: Evolution of the lipid trial protocol of the action to control cardiovascular risk in diabetes (ACCORD) trial. Am J Cardiol 2007, 99:56i–67i.Google Scholar
  36. 36.
    Niacin plus statin to prevent cardiovascular events (AIM-HIGH). Available at: http://www.clinicaltrials.gov/ct/show/NCT00120289. Accessed on September 2, 2008.
  37. 37.
    Brunzell JD: Hypertryglyceridemia. N Engl J Med 2007, 357:1009–1017.PubMedCrossRefGoogle Scholar
  38. 38.
    Sarwar N, Danesh J, Eiriksdottir G, et al.: Triglycerides and the risk of heart disease. Circulation 2007, 115:450–458.PubMedCrossRefGoogle Scholar
  39. 39.
    Pedersen TR, Olsson AG, Faergeman O, et al.: Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998, 97:1453–1460.PubMedGoogle Scholar
  40. 40.
    West of Scotland Coronary Prevention group: Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998, 97:1440–1445.Google Scholar
  41. 41.
    IDEAL: Lowering triglycerides in stable statin-treated CHD patients does not provide benefit [press release]. Heart wire/Cardiometabolic Risk; May 2, 2008.Google Scholar
  42. 42.
    Miller M, Cannon CP, Murphy SA, et al.; for the PROVE IT-TIMI 22 Investigators: Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008, 51:724–730.PubMedCrossRefGoogle Scholar
  43. 43.
    Marchioli R, Barzi F, Bomba E, et al.; for the GISSI-Prevenzione Investigators: Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction. Circulation 2002, 105:1897–1909.PubMedCrossRefGoogle Scholar
  44. 44.
    Brouwer IA, Zock PL, Camm J, et al.; for the SOFA Group: Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators. JAMA 2006, 295:2613–2619.PubMedCrossRefGoogle Scholar
  45. 45.
    Raitt MH, Connor WE, Morris C, et al.: Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators. JAMA 2005, 293:2884–2891.PubMedCrossRefGoogle Scholar
  46. 46.
    Grundy SM, Cleeman JI, Merz NB, for the coordinating Committee of the National Cholesterol Education Program: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004, 119:227–239.CrossRefGoogle Scholar
  47. 47.
    Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Effect of intensive compared witah moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA 2004, 291:1071–1080.PubMedCrossRefGoogle Scholar
  48. 48.
    Crouse JR, Raichlen JS, Riley WA, et al.; for the METEOR Study Group: Effect of rosuvastatin in progression of carotid intime-media thickness in lo0w-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007, 297:1344–1353.PubMedCrossRefGoogle Scholar
  49. 49.
    Guthrie RM, Martin DR: The safety of rosuvastatin: effects on renal and hepatic function. Expert Opin Drug Saf 2007, 6:573–581.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2009

Authors and Affiliations

  1. 1.Departments of Emergency Medicine, Internal Medicine, and PharmacologyThe Ohio State University 1380ColumbusUSA

Personalised recommendations